Anu Medical Distributors

Ujvira 160mg Injection is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein).

Ujvira 160mg Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

The most common side effects of this medicine include nausea, headache, rash, insomnia, and infection. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels. You must have to inform your doctor if you experience breathlessness, cough, shivering, swelling of legs and arm.

Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Ujvira 100mg Injection is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein).

Ujvira 100mg Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

The most common side effects of this medicine include nausea, headache, rash, insomnia, and infection. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels. You must have to inform your doctor if you experience breathlessness, cough, shivering, swelling of legs and arm.

Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Pertuzumab is used to treat certain types of breast cancer. It is also used to treat early stage breast cancer in patients who will be having surgery to remove the cancer. The types of cancers pertuzumab is used to treat are tumors that produce more than the normal amount of a certain substance called HER2 protein.Early Breast Cancer Neoadjuvant treatment Indicated in combination with trastuzumab (or trastuzumab hyaluronidase-oysk) and docetaxel for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancerInitial dose: Pertuzumab 840 mg IV infusion, THEN 420 mg IV infusion q3Weeks ANDTrastuzumab: 8 mg/kg IV infusion initially, then 6 mg/kg IV infusion q3Weeks ORTrastuzumab hyaluronidase-oysk: 600 mg/10,000 units (600 mg trastuzumab and 10,000 units hyaluronidase) SC q3Weeks irrespective of body weightDocetaxel: 75 mg/m² IV infusion initially; may increase to 100 mg/m² IV infusion q3Weeks if initial dose is well toleratedAdminister sequentially; pertuzumab and trastuzumab or trastuzumab hyaluronidase-oysk can be given in any order; taxane should be administered after pertuzumab and trastuzumab or trastuzumab hyaluronidase-oysk Neoadjuvant dosage regimens Administered q3Weeks for 3-6 cycles as part of 1 of the following treatment regimens for early breast cancer4 preoperative cycles of pertuzumab in combination with trastuzumab and docetaxel followed by 3 postoperative cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) as given in the NeoSphere trial3 or 4 preoperative cycles of FEC alone followed by 3 or 4 preoperative cycles of pertuzumab in combination with docetaxel and trastuzumab as given in TRYPHAENA and BERENICE trials 6 preoperative cycles of pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (TCH) (escalation of docetaxel above 75 mg/m² is not recommended) as given in TRYPHAENA trial4 preoperative cycles of dose-dense doxorubicin and cyclophosphamide (ddAC) alone followed by 4 preoperative cycles of pertuzumab in combination with paclitaxel and trastuzumab as given in BERENICE trialFollowing surgery, patients should continue to receive trastuzumab or trastuzumab hyaluronidase-oysk to complete 1 year of treatment (up to 18 cycles)Adjuvant treatment Indicated in combination with trastuzumab or trastuzumab hyaluronidase-oysk and chemotherapy for adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrenceInitial dose: Pertuzumab 840 mg IV infusion, THEN 420 mg IV infusion q3Weeks ANDTrastuzumab: 8 mg/kg IV initially, then 6 mg/kg IV q3Weeks ORTrastuzumab hyaluronidase-oysk: 600 mg/10,000 units (600 mg trastuzumab and 10,000 units hyaluronidase) SC q3Weeks irrespective of body weightFor a total of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity, whichever occurs first, as part of a complete regimen for early breast cancer, including standard anthracycline and/or taxane-based chemotherapy as given in APHINITY trialPertuzumab and trastuzumab or trastuzumab hyaluronidase-oysk should start on Day 1 of the first taxane-containing cycle

Product Specification Product DescriptionEstablished in year 2019, "Anu Medical Distributors" is the leading Wholesale Trader  of Pharmaceuticals Injection and Pharmaceuticals Tablets. They are known to make use of the best quality components, coupled with the latest technology. We have an advanced infrastructural base that is equipped with all the essential amenities. Thus, we aim to understand the diverse needs of our clients and offer suitable range of products. Being a client-centric firm, our main is to accomplish the customers' needs very competently.

Other Details:

• 440 mg multi-use vial.
• each vial of loyphilized powder contains 
• Trastuzumad - 440 mg
• L-Histidine hydrochioride monohydrate EP L-Histidine USP
• a,a-Trehalose dihydrate NF Polysorbate 20 NF . Each vial contains 7.2 ml sterile Bacteriostatic water for injection.
• Store the lyophilized powder and diluent between +2"C and +8"C. 

Product Specification Product DescriptionThalix 100 mg Capsules

Specifications :-

Product Name :- Thalix
Form :- Capsules
Strength :- 50 mg,100 mg 200 mg
Packing :- Pack Of 30 Capsules

Note :- Thalix Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug..............
Additional Information